Because the Th2 and Th22 immune pathways predominate in the AD inflammatory response, these biomarker candidates include Th2- and Th22-associated cytokines and chemokines including TARC/CCL17 and MDC/CCL22. The gene discussed is CCL22; the disease is Alzheimer disease.